Evidence map›Paper›PMID 31844845›Full record

ArticleACS applied bio materials2019

Click-Engineered, Bioresponsive, and Versatile Particle-Protein-Dye System.

Mary K Burdette, Ragini Jenkins, Yuriy P Bandera, Haley Jones, Isabell K Foulger, Ashley Dickey, Anna-Liisa Nieminen, Stephen H Foulger

Open access · greenAbstract read
In one paragraph

Article in ACS applied bio materials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mary K BurdetteDepartment of Materials Science and Engineering, Advanced Materials Research Laboratories, Clemson University, Anderson, South Carolina 29625, United States.
Ragini JenkinsDepartment of Materials Science and Engineering, Advanced Materials Research Laboratories, Clemson University, Anderson, South Carolina 29625, United States.
Yuriy P BanderaDepartment of Materials Science and Engineering, Advanced Materials Research Laboratories, Clemson University, Anderson, South Carolina 29625, United States.
Haley JonesDepartment of Materials Science and Engineering, Advanced Materials Research Laboratories, Clemson University, Anderson, South Carolina 29625, United States.
Isabell K FoulgerDepartment of Bioengineering, Clemson University, Clemson, South Carolina 29634, United States.
Ashley DickeyCenter for Optical Materials Science and Engineering Technologies, Advanced Materials Research Laboratories, Clemson University, Anderson, South Carolina 29625, United States.
Anna-Liisa NieminenDrug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina 29425, United States.
Stephen H FoulgerDepartment of Materials Science and Engineering, Advanced Materials Research Laboratories, Clemson University, Anderson, South Carolina 29625, United States.ORCID 0000-0002-4221-2154
Clemson University · USMedical University of South Carolina · US

Funding

Mechanisms of Cell Death after Photodynamic TherapyR01CA119079 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI NIEMINEN, ANNA-LIISA · 2007 to 2010
$1.1M
NCI NIH HHS R01 CA119079
6 · The paper itself

Abstract

We present a multifunctional polymer based nanoparticle platform for personalized nanotheranostic applications, which include photodynamic therapy and active targeting. In this system, poly(propargyl acrylate) (PA) particles were surface-modified with organic ligands and fluorophores (the payload) through an environmentally-sensitive linker. An azide modified bovine serum albumin (azBSA) was employed as the linker. This system prevents opsonization and, upon digestion, releases the payload. Attachment of the emitting payload to the particle through azide-modified bovine serum albumin (BSA) quenches emission, which can be again activated with digestion of the azBSA. The emission "turn-on" at a specific location will increase the signal-to-noise ratio. By utilizing human head and neck squamous carcinoma cells (UMSCC22A), photodynamic therapy studies with these particles gave promising reductions in cell growth. Additionally, the particle-protein-dye system is versatile as different fluorophores (such as silicon phthalocyanine or cyanine 3) can be attached to the protein and the same activation/deactivation behavior is observed. Active targeting can be employed to enhance the concentration of the payload in the designated tumor. Human lung carcinoma cells (A549) were utilized in toxicity studies where PA-azBSA particles were modified with a Survivin targeting ligand and indicated an enhanced cell death with the modified particles relative to the "free" Survivin targeting ligand.

Indexed as

active targetingbioresponsivemultifunctionalphotodynamic therapyprotein/nanoparticle conjugate

Identifiers

PMID31844845
PMCPMC6913539
OpenAlexW2954601980

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.